Alkermes plc

ALKS Healthcare Drug Manufacturers Specialty & Generic

Alkermes plc’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, down 5.25% from fiscal 2024. In the quarter to June 2026, revenue grew 27.0%, EPS fell 99.4% and free cash flow grew 1.13%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

41.22 1.12 +2.79%
Market cap
$6.7B
P/E
102×
Fwd P/E
−108×
Dividend yield
—
F-score
7/9
Altman Z
5.33
Beneish M
−3.29
Dividend safety
n/a
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 13.31 12.90 19.03
Piotroski F-Score
5 5 7 5 5 5 4 8 7 7
P/S ratio
11.40 9.38 4.18 2.74 3.05 3.19 3.81 2.86 3.05 3.12
Altman Z-Score
9.44 8.24 4.14 2.31 1.84 2.49 2.52 4.04 6.16 5.33
P/FCF ratio
0.00 0.00 150.78 0.00 76.77 50.60 0.00 13.45 11.71 9.57
Altman Z″-Score (non-manufacturers)
2.05 1.57 1.71 0.51 0.65 1.04 0.46 3.57 5.46 6.24
Beneish M-Score
(2.77) (2.77) (3.01) (3.31) (2.87) (2.32) (2.73) (2.10) (2.19) (3.29)
P/Operating CF
1,124.40 235.92 75.64 76.16 47.04 120.68 4,045.85 44.36 24.98 27.10
P/B ratio
7.03 7.04 3.91 2.95 2.97 3.36 4.06 3.96 3.25 2.53
Price to Tangible BV
10.64 9.92 5.16 3.81 3.67 3.96 4.59 4.26 3.44 2.66
EV/Sales
11.11 9.21 3.95 2.52 2.70 2.98 3.53 2.57 2.76 2.42
EV/EBITDA
0.00 0.00 952.62 0.00 0.00 19.86 54.63 8.74 9.56 12.73
EV/Operating CF
(129.85) 433.53 43.49 40.87 33.90 34.44 186.31 10.65 9.78 6.87
EV/FCF
(77.24) (260.41) 142.22 (163.99) 68.05 47.35 (227.81) 12.09 10.57 7.43
Quick Ratio
3.25 2.29 2.45 2.03 2.08 1.80 1.80 2.13 2.44 3.04
Current Ratio
3.73 2.78 2.89 2.46 2.54 2.25 2.27 2.86 3.04 3.55
Net Debt/EBITDA
1.87 3.08 (57.37) 2.71 11.78 (1.36) (4.39) (0.99) (1.67) (4.69)
Debt/Assets
16.43% 15.66% 15.30% 15.35% 14.10% 14.61% 14.93% 13.61% 0.00% 0.00%
Debt/Equity
0.23 0.23 0.24 0.26 0.26 0.27 0.28 0.24 0.00 0.00
Asset Turnover
0.42 0.51 0.60 0.65 0.55 0.59 0.56 0.81 0.74 0.65
Operating CF/Net income
0.31 (0.12) (0.71) (0.37) (0.75) (2.11) (0.13) 1.13 1.20 2.15
Capex/Depreciation
(0.46) (0.52) (0.66) (1.12) (0.51) (0.37) (0.49) (0.64) (1.16) (1.45)
Interest Coverage
(14.01) (12.32) (6.42) (12.90) (12.98) 8.71 (0.47) 17.98 18.63 20.69
ROE
(16.52%) (13.10%) (11.74%) (17.43%) (10.30%) (4.42%) (14.68%) 31.67% 27.52% 14.72%
ROA
(11.64%) (8.96%) (7.69%) (10.83%) (5.90%) (2.42%) (7.94%) 17.35% 17.51% 10.64%
ROIC
(13.10%) (8.80%) (6.80%) (13.25%) (9.94%) 7.01% (0.52%) 35.95% 36.86% 31.75%
Return on Tangible Assets
(24.71%) (19.68%) (14.61%) (21.07%) (10.84%) (5.17%) (18.50%) 29.84% 31.17% 15.03%
Average Days of Receivables
93.54 94.38 97.47 80.14 96.68 97.39 94.54 72.96 90.11 82.61
Research and Development Expense of Revenue
51.92% 45.71% 38.88% 43.80% 37.99% 24.79% 24.53% 16.28% 15.75% 21.95%
Selling, General and Administrative Expense of Revenue
50.17% 46.67% 48.11% 51.19% 51.87% 46.83% 53.13% 41.47% 41.42% 47.53%
Intangible Assets out of Total Assets
0.24 0.19 0.16 0.13 0.10 0.08 0.06 0.04 0.04 0.03
Share Based Compensation of Revenue
12.66% 9.29% 9.63% 8.62% 8.68% 7.47% 8.48% 6.07% 6.20% 6.69%
Graham Net Nets
0.03 0.03 0.07 0.08 0.07 0.04 0.05 0.12 0.17 0.27
Graham Number
0.00 0.00 0.00 0.00 0.00 0.00 0.00 18.71 21.08 19.11
Earnings Yield
(2.44%) (1.87%) (3.02%) (6.18%) (3.51%) (1.29%) (3.71%) 7.51% 7.75% 5.25%
Free Cash Flow Yield
(1.26%) (0.38%) 0.66% (0.56%) 1.30% 1.98% (0.41%) 7.43% 8.54% 10.45%
Revenue per Share
4.92 5.89 7.05 7.46 6.54 7.29 6.79 10.01 9.42 8.96
Operating CF per Share
(0.42) 0.13 0.64 0.46 0.52 0.63 0.13 2.41 2.66 3.16
Capex per Share
(0.29) (0.33) (0.44) (0.57) (0.26) (0.18) (0.23) (0.29) (0.20) (0.24)
Free Cash Flow per Share
(0.71) (0.21) 0.20 (0.11) 0.26 0.45 (0.11) 2.13 2.46 2.92
Cash per Share
3.28 2.83 3.48 3.41 4.00 3.33 3.72 4.65 4.54 8.01
Shareholders Equity per Share
7.98 7.84 7.55 6.91 6.72 6.91 6.37 7.24 8.86 11.05
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
7.98 7.84 7.55 6.91 6.72 6.91 6.37 7.24 8.86 11.05
Free Cash Flow
(107.26) (31.95) 30.36 (17.96) 41.27 72.98 (17.21) 353.66 406.10 481.42
Working Capital
578.69 517.72 643.48 570.86 672.71 590.88 632.56 965.29 950.16 1,385.72
Capital Expenditures
(43.46) (51.14) (68.92) (90.04) (41.58) (28.73) (38.25) (47.69) (33.02) (39.33)
Net Current Asset Value
273.74 214.43 329.53 242.01 228.22 150.27 210.08 551.97 824.77 1,261.46
EV/EBIT
0.00 0.00 0.00 0.00 0.00 35.84 0.00 10.32 10.21 14.09
Capex to Sales
0.06 0.06 0.06 0.08 0.04 0.02 0.03 0.03 0.02 0.03
Price to Operating Income
0.00 0.00 0.00 0.00 0.00 38.30 0.00 11.49 11.31 18.15
Other line items
Depreciation/Fixed assets
0.36 0.35 0.33 0.22 0.23 0.23 0.35 0.33 0.13 0.12
Cash ROIC
(5.39%) (1.67%) 1.53% (0.95%) 2.09% 3.75% (0.88%) 15.60% 18.32% 15.34%
Accounts Receivable Turnover
4.30 4.25 4.16 4.26 3.90 3.99 3.70 5.36 4.34 4.11
Accounts Payable Turnover
0.70 0.63 0.57 0.51 0.45 0.64 1.02 1.10 1.15 0.83
Inventory Turnover
2.61 1.98 1.92 1.88 1.57 1.43 1.31 1.38 1.33 1.04
Average Days of Payables
572.01 674.97 690.53 754.82 843.68 385.66 368.38 347.00 275.73 537.99
Days of Inventory on Hand
174.04 220.01 186.61 205.99 257.38 278.08 303.66 268.89 272.10 365.31
Average Receivables
173.29 212.35 262.91 274.65 266.11 294.17 300.58 310.22 358.50 359.28
Average Payables
187.90 246.61 309.96 353.40 392.60 310.33 214.29 230.33 212.95 237.45
Average Inventory
50.70 78.14 91.74 96.00 113.77 138.04 165.88 183.91 184.65 189.76
Average Assets
1,791.08 1,761.83 1,811.12 1,815.21 1,877.57 1,987.11 1,994.23 2,050.10 2,095.90 2,271.28
Average Common Equity
1,261.88 1,206.14 1,187.05 1,128.36 1,076.21 1,089.78 1,078.17 1,123.22 1,333.83 1,642.14

Fold the line items

Columns are period end dates